hepatitis C


Gilead's Sovaldi patent takes a hit in Europe

Already facing a slowdown for its superstar hep C meds, Gilead Sciences may be a bit more tense this week. A key patent for Sovaldi is under fire in Europe, and officials have already pared back the blockbuster med’s patent claims.